PMID- 24569549
OWN - NLM
STAT- MEDLINE
DCOM- 20141118
LR  - 20220408
IS  - 1752-2978 (Electronic)
IS  - 1752-296X (Linking)
VI  - 21
IP  - 2
DP  - 2014 Apr
TI  - The nonhuman primate as a model for type 2 diabetes.
PG  - 89-94
LID - 10.1097/MED.0000000000000043 [doi]
AB  - PURPOSE OF THE REVIEW: Although rodent models provide insight into the mechanisms 
      underlying type 2 diabetes mellitus (T2DM), they are limited in their 
      translatability to humans. The nonhuman primate (NHP) shares important metabolic 
      similarities with the human, making it an ideal model for the investigation of 
      type 2 diabetes and use in preclinical trials. This review highlights the key 
      contributions in the field over the last year using the NHP model. RECENT 
      FINDINGS: The NHP has not only provided novel insight into the normal and 
      pathological processes that occur within the islet, but has also allowed for the 
      preclinical testing of novel pharmaceutical targets for obesity and T2DM. 
      Particularly, administration of fibroblast growth factor-21 in the NHP resulted 
      in weight loss and improvements in metabolic health, supporting rodent studies 
      and recent clinical trials. In addition, the NHP was used to demonstrate that a 
      novel melanocortin-4 receptor agonist did not cause adverse cardiovascular 
      effects. Finally, this model has been used to provide evidence that glucagon-like 
      peptide-1-based therapies do not induce pancreatitis in the healthy NHP. SUMMARY: 
      The insight gained from studies using the NHP model has allowed for a better 
      understanding of the processes driving T2DM and has promoted the development of 
      well tolerated and effective treatments.
FAU - Pound, Lynley D
AU  - Pound LD
AD  - aDivision of Diabetes, Obesity, & Metabolism bDivision of Reproductive & 
      Developmental Sciences, Oregon National Primate Research Center, Beaverton, 
      Oregon, USA.
FAU - Kievit, Paul
AU  - Kievit P
FAU - Grove, Kevin L
AU  - Grove KL
LA  - eng
GR  - R24 DK090964/DK/NIDDK NIH HHS/United States
GR  - P51 OD011092/OD/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - England
TA  - Curr Opin Endocrinol Diabetes Obes
JT  - Current opinion in endocrinology, diabetes, and obesity
JID - 101308636
RN  - 0 (Hypoglycemic Agents)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Experimental/*drug therapy/pathology
MH  - Diabetes Mellitus, Type 2/*drug therapy/pathology
MH  - Diet, High-Fat
MH  - Disease Models, Animal
MH  - Female
MH  - Glucagon-Like Peptide 1/*agonists
MH  - Hypoglycemic Agents/*pharmacology
MH  - Insulin-Secreting Cells
MH  - Macaca mulatta
MH  - Male
MH  - Pancreatitis/*chemically induced
MH  - Weight Loss/*drug effects
EDAT- 2014/02/27 06:00
MHDA- 2014/11/19 06:00
CRDT- 2014/02/27 06:00
PHST- 2014/02/27 06:00 [entrez]
PHST- 2014/02/27 06:00 [pubmed]
PHST- 2014/11/19 06:00 [medline]
AID - 01266029-201404000-00004 [pii]
AID - 10.1097/MED.0000000000000043 [doi]
PST - ppublish
SO  - Curr Opin Endocrinol Diabetes Obes. 2014 Apr;21(2):89-94. doi: 
      10.1097/MED.0000000000000043.